Filing Details
RECURSION PHARMACEUTICALS, INC. (NASDAQ:RXRX) filed a Form 8-K with the Securities and Exchange Commission on October 15, 2026, disclosing a material event.
8k filedNASDAQ:RXRX
RECURSION PHARMACEUTICALS, INC. (RXRX) Reports Material Event to SEC
RECURSION PHARMACEUTICALS, INC. (NASDAQ:RXRX) filed a Form 8-K with the Securities and Exchange Commission on October 15, 2026, disclosing a material event.
At publication ·
What changed
RECURSION PHARMACEUTICALS, INC. (NASDAQ:RXRX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Recursion Pharmaceuticals filed a Form 8-K with the SEC on October 15, 2026, disclosing a material event requiring shareholder attention.
- The stock traded at $4.16 per share with a market capitalization of $1.8 billion at the time of the filing.
- Material events reported in 8-K filings typically include leadership changes, acquisitions, asset sales, or guidance changes.
Market Context
RECURSION PHARMACEUTICALS, INC.'s stock currently trades at $4.16 with a market capitalization of $1.8B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for RECURSION PHARMACEUTICALS, INC.'s stock.
All SEC filings for RECURSION PHARMACEUTICALS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View RXRX Stock Page
Frequently Asked Questions
Where can I read RXRX's SEC filings?
Browse all filings on our RXRX SEC filings page.
What types of SEC filings does RECURSION PHARMACEUTICALS, INC. file?
Public companies like RECURSION PHARMACEUTICALS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.